A Phase 2 interventional study of Hydroxycarbamide in Sickle Cell Disease, sponsored by Theravia. Completed at 3 sites in France. Open to participants aged 2 Years to 6 Years. Per ClinicalTrials.gov, last updated 2022-11-23.
Sponsored by Theravia (part of Norgine) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 59 studies testing hydroxyurea in Anemia, Sickle Cell — 8 open to participants now, 14 under way, 1 of them phase 3. Hydroxyurea · Anemia, Sickle Cell.
Among the 59 studies testing hydroxyurea in Anemia, Sickle Cell, this one is the 40th largest by enrollment of the 57 interventional ones that give a count, is one of 2 that started in 2022, is one of 20 in phase 2, and was the 52nd registered.
1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.
Browse Anemia, Sickle Cell studies →8 of the 59 studies testing hydroxyurea in Anemia, Sickle Cell are open now, in 6 countries. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
Ages up to 22
Children's Hospital Medical Center, Cincinnati · Sites in Uganda
Ages 11–18
Theravia · Sites in France, French Guiana
Ages 9 mo–11 yrs
Vanderbilt University Medical Center · Sites in Nigeria
Ages 5–12
Brown University · Sites in Angola
Ages 6 mo–12 yrs
By country, each count listing its studies:
Hydroxyurea: first FDA approval 1967 (DROXIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: 2 Years to 6 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
59 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 15 · Phase 2 29 · Phase 3 12 · Phase 4 5
First in 1984; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 33 is below the median of 40 across 769 interventional studies indexed under Anemia, Sickle Cell.
Median enrollment 50 across the 57 interventional studies. Of the 43 that completed or were terminated, 18 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 59 have an industry lead sponsor. The 10 most frequent:
This study is registered under Theravia, one of the names counted as Norgine. Under that name alone:
Theravia is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Norgine has 7 studies filed under Anemia, Sickle Cell — fewer than ten, so there is no comparison to draw.
4 of the studies testing hydroxyurea in Anemia, Sickle Cell that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT02286154Children's Hospital Medical Center, CincinnatiTherapeutic Response Evaluation and Adherence Trial (TREAT) | 2026-12 |
| NCT05662098Children's Hospital Medical Center, CincinnatiAlternative Dosing And Prevention of Transfusions (ADAPT) | 2026-12-31 |
| NCT06171217Children's Hospital Medical Center, CincinnatiRealizing Effectiveness Across Continents With Hydroxyurea | 2027-10-04 |
Add all 4 to your calendar (.ics) → With an account.
Among the 59 studies testing hydroxyurea in Anemia, Sickle Cell, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a prospective, interventional, phase II, open-label, multicentre, national, non-comparative study of a single administration of the new dispersible form of hydroxycarbamide at the usual dose in children with sickle cell disease who are already treated with the current form of hydroxycarbamide (Siklos® 100 mg and/or 1000 mg film-coated tablets).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Single arm study with a single administration of hydroxycarbamide
Drug: Hydroxycarbamide
Single administration of the new dispersible form of hydroxycarbamide at the usual dose in children with sickle cell disease who are already treated with the current form of hydroxycarbamide.
Acceptability score
Acceptability score evaluated by the parent(s) of the child (2-6 years old) and by the child (4-6 years old)
Time frame: At Day 1 (inclusion visit at study drug administration)
Percentage of children with acceptable acceptability score (neutral to positive scores)
Neutral to positive scores reported by the parent(s) of the child (2-6 years old), and by the child (4-6 years old)
Time frame: At Day 1 (inclusion visit at study drug administration)
Distribution of the scores related to the ease of administration
Score reported by parent(s), based on a 5-point Likert scale,
Time frame: At Day 1 (inclusion visit at study drug administration)
Distribution of the scores related to the ease of preparation including the ease of constitution of the liquid form and the ease to follow the prescription
Score reported by the parent(s) based on a 5-point Likert scale,
Time frame: At Day 1 (inclusion visit at study drug administration)
Score related to the usefulness of the dispersible form, compared with the tablets currently used
Score reported by the parent(s), based on a 5-point Likert scale
Time frame: At Day 1 (inclusion visit at study drug administration)
Free comments collected by the investigator
Questions from child/parent, reactions before/after drug intake
Time frame: At Day 1 (inclusion visit at study drug administration)
Number of adverse events
Number of adverse events and percentage of patients reporting at least one adverse event
Time frame: At Day 1 (inclusion visit at study drug administration)
Plan to share: No
No publications or documents are linked to this record.
Ran from Jul 2022 to primary completion in Oct 2022, 3 months.
Of 34 industry-sponsored phase 2 interventional studies under Anemia, Sickle Cell, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 41. This study's 3 months is below that.
Counting every sponsor, half of 93 studies reached it within 46 months; a quarter within 24 and three quarters within 73.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hydroxyurea